You are browsing articles on the topic of Anticoagulation Archives - CardioExchange

Avatar of Peter B Berger, MD

Can Bivalirudin Stand the HEAT? (14 Jul 2014)

Voices

Peter B Berger, MD

Harlan Krumholz interviews Peter Berger, an editorialist for the HEAT-PPCI study, about the paper’s findings.

Avatar of Larry Husten, PHD

HEAT-PPCI: Heparin Beats Bivalirudin in Primary PCI (7 Jul 2014)

News

Although there is broad consensus in the medical community that primary PCI is the best treatment for MI patients when it can be delivered promptly, there is no agreement about the best accompanying drug regimen, which usually entails a combination of antiplatelet and antithrombotic drugs. The role of one antithrombotic, bivalirudin (Angiomax, The Medicines Company) has…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Physician's First Watch, CardioExchange Staff

To Screen or Not for AF: Is That the Question? (26 Jun 2014)

News

Up to one third of ischemic strokes are of uncertain etiology or “cryptogenic,” meaning that there is no overt explanation such as severe carotid stenosis, intracranial stenosis, or documented atrial fibrillation (AF). For some of these patients, intermittent AF may be present and could explain the ischemic stroke. This issue has been addressed by two…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Jay

A Meta-Look at Thrombolysis vs. Conventional Anticoagulation for PE (17 Jun 2014)

Voices

Jay Giri, MD, MPH and Saurav Chatterjee, MD

Jay Giri and Saurav Chatterjee discuss their meta-analysis of trials comparing thrombolytic therapy and conventional anticoagulation in patients at intermediate risk for pulmonary embolism.

Avatar of Larry Husten, PHD

Mixed Results for Thrombolysis in Pulmonary Embolism (17 Jun 2014)

News

  The role of thrombolytic therapy for the treatment of pulmonary embolism has been unclear, as it has been difficult to measure the precise balance between enhanced clot-dissolving efficacy and greater bleeding risk produced by thrombolysis when compared with conventional anticoagulation. A new meta-analysis published in JAMA analyzed data from 16 randomized trials including 2115 patients….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Nicolas

Lytics in STEMI: A New Analysis of Data from FAST-MI (19 May 2014)

Voices

Nicolas Danchin, MD, PhD and John Ryan, MD

French researchers analyze data from FAST-MI and conclude that a fibrinolysis-based strategy may be valid for some patients with STEMI.

Avatar of Larry Husten, PHD

FDA Study Provides Some Reassurance About Boehringer Ingelheim’s Pradaxa (13 May 2014)

News

In the latest development in its ongoing review of the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim), the FDA today offered largely reassuring news about the sometimes controversial drug. The FDA study of over 134,000 Medicare patients found that dabigatran was associated with a reduced risk for ischemic stroke, bleeding in the brain, and death, compared with…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Novel Antiplatelet Agent Vorapaxar Gains FDA Approval (8 May 2014)

News

The FDA today approved vorapaxar (Zontivity), Merck’s once-troubled platelet receptor antagonist, to reduce the risk of myocardial infarction (MI), stroke, cardiovascular death, and revascularization procedures. The drug is approved for use in people with a history of MI or peripheral arterial disease. The approval represents an amazing turnaround for a drug that has experienced nearly as many…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Dabigatran Approved for Treatment of DVT and PE (7 Apr 2014)

News

Boehringer Ingelheim announced on Monday that the FDA has approved dabigatran (Pradaxa) for the treatment of venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. All three of the new oral anticoagulants — dabigatran, rivaroxaban…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Apixaban Gains Indication for DVT Prophylaxis After Knee and Hip Replacement Surgery (14 Mar 2014)

News

The FDA has approved a new indication for apixaban (Eliquis), the anticoagulant drug manufactured by Bristol-Myers Squibb and Pfizer. The new indication is for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism in patients who have undergone hip or knee replacement surgery. The DVT prophylaxis indication joins the previously approved indication of stroke prevention in patients who have…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.